Pharmaceuticals Mexico

Mexico Severe Asthma Biologics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Mexico Severe Asthma Biologics Market Industry Trends and Forecast to 2034: Segmented by (Target, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Mexico · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $224.2 Mn Placeholder estimate
Estimate 2025 $246.6 Mn 1.7% of the global market
Projected 2034 $581.5 Mn 135.8% Adds $334.9 Mn over 9 forecast years
CAGR 2025–2034 10.0% Faster than 60% of 180 Pharmaceuticals markets here
Key players 5
  • Mexico is 1.7% of the global market.
  • In Latin America, the largest is Brazil at $381.6 Mn.
  • Fastest growing: Brazil at 11% a year.
  • Mexico ranks 3rd of 3 by size in Latin America.

Market size projection

Mexico

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$334.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Severe Asthma Biologics Market market size by year, Mexico
YearMarket sizeChange that yearSince 2025
2024 (estimate) $224.2 Mn — —
2025 (base) $246.6 Mn +$22.4 Mn —
2026 (forecast) $271.3 Mn +$24.7 Mn +10%
2027 (forecast) $298.4 Mn +$27.1 Mn +21%
2028 (forecast) $328.2 Mn +$29.8 Mn +33.1%
2029 (forecast) $361.0 Mn +$32.8 Mn +46.4%
2030 (forecast) $397.1 Mn +$36.1 Mn +61.1%
2031 (forecast) $436.9 Mn +$39.7 Mn +77.2%
2032 (forecast) $480.5 Mn +$43.7 Mn +94.9%
2033 (forecast) $528.6 Mn +$48.1 Mn +114.4%
2034 (forecast) $581.5 Mn +$52.9 Mn +135.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Mexico Severe Asthma Biologics Market Analysis at a glance
Market size, 2025$246.6 Mn placeholder estimate
Forecast, 2034$581.5 Mn placeholder estimate
Growth (CAGR), 2025–203410.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledAsthma Biologics
SegmentsTarget, age and end user (see all)
Key playersSanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC, Novartis AG (see all)
Regulator in MexicoCOFEPRISSource: COFEPRIS. Checked 14 Nov 2026.
Active clinical trials5 in MexicoSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Mexico Severe Asthma Biologics Market Analysis Executive Summary

Severe asthma biologics are injections that block immune signals driving severe asthma attacks.

Key segments of the severe Asthma Biologics market include target (IL-5, IL-4/IL-13 and IgE) and age (Children and Adults).

Bar chart: Mexico Severe Asthma Biologics market size, 2024–2034, placeholder estimates. $224.2 Mn in 2024, $246.6 Mn in 2025 and $581.5 Mn in 2034, 10.0% CAGR.
Mexico Severe Asthma Biologics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Mexico Severe Asthma Biologics Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.

Opportunity

Earlier screening, new drug classes and home-based care give the severe Asthma Biologics market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the severe Asthma Biologics market.

Competitive Landscape for Severe Asthma Biologics Market in Mexico

The severe Asthma Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Severe Asthma Biologics Market in Mexico

Severe Asthma Biologics in Mexico: rules, payment and research

Medicines need a sanitary registration from COFEPRIS before sale.⁠[1] Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security.⁠[2] ClinicalTrials.gov lists 5 studies on Severe Asthma Biologics that are recruiting, active or about to start in Mexico.⁠[3]

[1] COFEPRIS. Checked 14 Nov 2026.

[2] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for severe Asthma Biologics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Mexico.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Severe Asthma Biologics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Severe Asthma Biologics in context

Mexico compared

  • Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 8.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 4 countries we cover in Latin America.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Severe Asthma Biologics market in Mexico?
Placeholder estimate: about $246.6 Mn in 2025, rising to about $581.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Severe Asthma Biologics market in Mexico growing?
Placeholder estimate: about 10.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Severe Asthma Biologics market report cover?
The report splits the market by target (IL-5, IL-4/IL-13, IgE, TSLP), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Severe Asthma Biologics market?
Key players include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK PLC and Novartis AG.
What is driving the Severe Asthma Biologics market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.
Who regulates Severe Asthma Biologics in Mexico?
Medicines need a sanitary registration from COFEPRIS before sale. Source: COFEPRIS. Checked 14 Nov 2026.
How is healthcare paid for in Mexico?
Public care comes through IMSS for formal workers, ISSSTE for public employees, and IMSS-Bienestar for people without social security. Source: Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
How many clinical trials on Severe Asthma Biologics are running in Mexico?
5 studies are recruiting, active or about to start in Mexico, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.
How much research is published on Severe Asthma Biologics?
PubMed lists 322 papers on Severe Asthma Biologics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Mexico

See all

Related on respiratory and biologics and biosimilars

See the topic